Fuan Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 166 million yuan, a decrease of 44.87%
According to the Zhitong Finance APP, Fuan Pharmaceutical released its third-quarter report for 2025. The company's operating income for the first three quarters was 1.315 billion yuan, a year-on-year decrease of 34.08%. The net profit attributable to shareholders of the listed company was 166 million yuan, a year-on-year decrease of 44.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 148 million yuan, a year-on-year decrease of 47.53%. The basic earnings per share were 0.14 yuan
According to the Zhitong Finance APP, Fuan Pharmaceutical (300194.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.315 billion yuan, a year-on-year decrease of 34.08%. The net profit attributable to shareholders of the listed company was 166 million yuan, a year-on-year decrease of 44.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 148 million yuan, a year-on-year decrease of 47.53%. The basic earnings per share were 0.14 yuan
